Seeing a Future in Content Chips, Full Moon To Target Pharma with Antibody Array Debut

The antibody arrays represent a sea change in Full Moon Bio’s business as it embraces what it believes to be the next wave in microarray technology and looks to expand beyond its traditional role as a substrate provider.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.